Roche Secures Haosen Pharma, Breaking Waves in Innovative Drug Ocean
October 17, 2025Haosen Pharmaceutical Group Limited announced a licensing agreement with Roche regarding HS-20110. This drug is an ADC targeting CDH17 with a payload of a clinically validated TOPOi. Haosen Pharma granted Roche exclusive rights outside Mainland China, Hong Kong, Macao, and Taiwan to develop and commercialize HS-20110.…
This data comes from the ChinaPulse.com media intelligence and smart news insights monitoring platform.
Original URL: Click here to visit original article